The Cigna Group (CI) Stock Price, News, Analysis

Technical Score (1D)

SELL

News Sentiment

BULLISH

What’s happening to CI today?

Bernstein analysts have upgraded Cigna Group (CI) to Outperform, raising their price target to $358 from $307, indicating increased confidence in the company's prospects and a more bullish stance. This analyst upgrade, which occurred over the past day, suggests a potentially more favorable outlook for Cigna's future performance and valuation. Investors will be closely monitoring Cigna's core health services business, as recent share price weakness has raised questions about potential undervaluation or priced-in future growth challenges. The market reaction to this upgrade will be a key focus in the coming trading days.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

The Cigna Group announced CEO David M. Cordani will retire July 1, 2026, with Brian Evanko, current president and COO, succeeding him. This planned transition emphasizes continuity in data-driven healthcare services, leveraging Evanko's extensive experience across key business segments. Investors will monitor how this leadership change impacts the company's investment narrative and long-term strategy, particularly its reliance on Evernorth and the PBM model.

What did this article say?

Cigna Group's stock has seen a notable decline, with returns showing weakness over the past week, month, year, and five years. This performance is contextualized by broader market sentiment towards healthcare stocks. Despite recent price drops, the article suggests a mixed picture regarding investor reassessment of the company's value over different periods.

What did this article say?

Cigna Group (CI) presents a compelling valuation with a forward P/E ratio of 8.61x, notably below the industry average of 13.45x. Despite a modest year-to-date share price decline, the company's performance has outpaced the broader industry. Analysts project continued revenue growth and a slight increase in earnings for 2026, supported by consistent earnings beats in recent quarters.

What did this article say?

The Cigna Group (CI) is highlighted as a top value stock, with analysts viewing recent leadership changes as part of strategic continuity. Despite a prior stock decline, the company shows upside potential and has outperformed its sector. The timing of the CEO transition may be a surprise to some investors, according to Barclays.

What did this article say?

Cigna Group (CI) shares have experienced recent weakness, with notable declines over the past week, month, and three months. This price action necessitates a closer examination of its core health services business and overall valuation. The current share price of $265.88 reflects fading momentum, with a 1-year total shareholder return showing a significant decline.

What did this article say?

Bernstein has upgraded its rating on Cigna Group (CI), reflecting a positive shift in analyst sentiment. This upgrade suggests a more optimistic view on the company's future performance and strategic positioning within the healthcare sector. Investors should monitor Cigna's upcoming earnings reports and any further commentary from Bernstein regarding the rationale behind this rating change.

What did this article say?

Bernstein has upgraded Cigna's rating, signaling a positive outlook from the analyst firm. This upgrade suggests a potential shift in investor sentiment and could influence trading activity. Investors will be watching for further commentary on Cigna's strategic positioning and financial performance.

What did this article say?

Bernstein has upgraded Cigna (CI) from Market Perform to Outperform, signaling increased confidence in the company's prospects. The firm also raised its price target for CI to $358, up from $307. This analyst action reflects a positive outlook on Cigna's future performance and valuation.

What did this article say?

Bernstein has upgraded Cigna Group (CI) from Market Perform to Outperform, signaling increased conviction in the company's prospects. The analyst firm also raised its price target for CI shares from $307 to $358. This move suggests a positive outlook on Cigna's future performance and valuation.

What did this article say?

Argus Research has lowered its price target for The Cigna Group (CI) to $289.00 while maintaining a BUY investment rating. The firm's assessment highlights strong ratings in industry, safety, and financial strength, with medium ratings for management, growth, and value. This adjustment suggests a cautious but optimistic outlook on the company's prospects.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

CI·The Cigna Group

What’s happening to CI today?

Recent News Coverage

Recent News Coverage